Zoho Sheet

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62

Watson Pharma ($M)		30 Jun 2009	30 Jun 2009	31 Mar 2009	31 Dec 2008	30 Sep 2008	30 Jun 2008	31 Mar 2008	31 Dec 2007	30 Sep 2007	30 Jun 2007	31 Mar 2007
		(actual)	(predicted)	(actual)	(actual)	(actual)	(actual)	(actual)	(actual)	(actual)	(actual)	(actual)
Revenue		$678	$661	$667	$645	$641	$623	$627	$627	$595	$603	$672
Operating Expenses
	Cost of Goods Sold	($393)	($383)	($389)	($376)	($387)	($360)	($380)	($373)	($346)	($360)	($425)
	Depreciation	($22)	($22)	($22)	($20)	($20)	($20)	($20)	($44)	($44)	($44)	($44)
	Research & development	($43)	($45)	($42)	($48)	($45)	($39)	($38)	($36)	($36)	($36)	($38)
	Selling, General & Administrative	($128)	($115)	($135)	($111)	($101)	($104)	($107)	($108)	($112)	($97)	($103)
	Special operating charges
Operating income		$92	$96	$80	$90	$87	$99	$82	$66	$56	$66	$62
	Gains on investments					$8
	Gains on asset sales	($0)	$2	$2	($0)	($0)				$6
	Net interest and other income	($1)	($2)	($2)	($4)	($1)	($3)	($0)	($6)	($7)	($8)	($10)
Income before taxes		$91	$96	$80	$87	$94	$96	$82	$60	$55	$57	$52
	Provisions for income taxes	($38)	($33)	($31)	($30)	($23)	($36)	($31)	($21)	($21)	($21)	($20)	-$7.76
Net income before adjustments		$53	$62	$49	$56	$71	$60	$51	$38	$35	$36	$32
	Minority interests
	Income from discontinued ops
Net income		$53	$62	$49	$56	$71	$60	$51	$38	$35	$36	$32
Earnings Per Share		$0.45	$0.53	$0.42	$0.48	$0.60	$0.51	$0.43	$0.33	$0.29	$0.31	$0.27

Shares Outstanding		118.8	118.0	118.2	118.0	118.0	117.7	117.4	117.4	117.4	117.1	116.6
Price per share		$33.69		$31.11	$26.57	$28.50	$27.17	$29.32	$27.14	$32.40	$32.53	$26.43
Market Value		$4,002	$0	$3,677	$3,135	$3,363	$3,197	$3,442	$3,186	$3,804	$3,809	$3,082

Revenue growth from year-earlier		8.9%	6.2%	6.5%	2.9%	7.7%	3.3%	-6.6%
Operating income growth from year-earlier		-7.4%	-3.5%	-2.5%	36.8%	55.9%	50.6%	32.4%
Net income growth from year-earlier		-12.1%	3.1%	-3.0%	46.8%	105.3%	65.6%	60.2%
EPS growth from year earlier		-13.0%	2.8%	-3.7%	46.1%	104.3%	64.8%	59.1%

CGS/Revenue		58.0%	58.0%	58.2%	58.3%	60.3%	57.8%	60.6%	59.5%	58.3%	59.8%	63.2%
Gross Margin		42.0%	42.0%	41.8%	41.7%	39.7%	42.2%	39.4%	40.5%	41.7%	40.2%	36.8%
Depreciation/Revenue		3.3%	3.3%	3.3%	3.1%	3.2%	3.2%	3.2%	7.0%	7.4%	7.3%	6.5%
R&D/Revenue		6.3%	6.8%	6.3%	7.4%	7.1%	6.3%	6.1%	5.7%	6.0%	5.9%	5.6%
SG&A/Revenue		18.9%	17.4%	20.2%	17.2%	15.8%	16.8%	17.0%	17.3%	18.9%	16.1%	15.4%
Income tax rate		41.5%	35.0%	38.6%	34.9%	24.4%	37.1%	38.1%	35.8%	37.5%	36.6%	38.8%


Revenue (TTM)		$2,631	$2,614	$2,576	$2,536	$2,518	$2,472	$2,452	$2,497
Net Income (TTM)		$230	$239	$237	$238	$220	$184	$160	$141
EPS (TTM)		$1.94	$2.02	$2.01	$2.02	$1.87	$1.57	$1.36	$1.20

Revenue growth year-on-year		6.45%	5.77%	5.06%	1.56%	N/A	N/A	N/A	N/A
Net Income growth year-on-year		24.79%	29.77%	47.99%	69.03%	N/A	N/A	N/A	N/A

Price/Revenue (TTM)		1.52	0	1.43	1.24	1.34	1.29	1.4	1.28
Price/Earnings (TTM)		17.44	0	15.53	13.15	15.26	17.38	21.5	22.59

Sheet1

Sheet2

Sheet3